PharmaCyte Biotech has received approval from Nasdaq to list its common stock under the symbol “PMCB.” The company plans to conduct an underwritten public offering of its common stock, which may include pre-funded warrants. H.C. Wainwright will manage the offering, which might also include a 30-day option for the underwriter to purchase additional shares. The proceeds will fund activities to address the FDA's clinical hold on its Investigational New Drug application for a Phase 2b trial in pancreatic cancer and for general working capital.
PharmaCyte Biotech (OTCQB: PMCBD) announced recognition from three independent publications discussing its pancreatic cancer treatments using the Cell-in-a-Box® technology. CEO Kenneth L. Waggoner confirmed the company remains above the price requirement for a potential Nasdaq uplist. Notable findings from clinical trials highlight median survival doubling with lower doses of ifosfamide. Recent publications validate PharmaCyte's approach, citing significant advancements in treating pancreatic cancer. The company aims to begin a Phase 2b clinical trial pending FDA approval.
PharmaCyte Biotech, Inc. (OTCQB: PMCBD, PMCB) announced that its original cytochrome P450 expressing cells from its Master Cell Bank have retained viability and enzymatic activity after three years in liquid nitrogen. This data is vital for the ongoing development of its CypCaps product, a treatment for cancer utilizing encapsulated cells to activate chemotherapy drugs like ifosfamide efficiently.
The study will continue for three more years to ensure the stability of these cells for future clinical trials.